ceftazidime

ceftazidime is a third-generation cephalosporin with broad-spectrum activity against gram-negative bacteria.

intravenous ceftazidime is commonly prescribed for severe hospital-acquired infections.

the recommended ceftazidime dosage must be adjusted for patients with renal impairment.

ceftazidime resistance has been increasingly reported in pseudomonas aeruginosa isolates.

empirical ceftazidime therapy is often initiated before culture results become available.

ceftazidime demonstrates excellent penetration into cerebrospinal fluid.

skin testing should be performed before administering ceftazidime to patients with penicillin allergy.

ceftazidime is frequently combined with other antibiotics for synergistic effects.

the pharmacokinetics of ceftazidime allow for once-daily dosing in certain populations.

ceftazidime has proven highly effective in treating complicated urinary tract infections.

close monitoring is essential during ceftazidime treatment to detect potential neurotoxicity.

ceftazidime remains a first-line agent for febrile neutropenia in cancer patients.